Vera Therapeutics, INC. (VERA) — SEC Filings

Q: What are the key financial highlights for Vera Therapeutics, INC.?

Key financial highlights for Vera Therapeutics, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Vera Therapeutics, INC.?

Key executives at Vera Therapeutics, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Vera Therapeutics, INC. stock?

Risk factors for Vera Therapeutics, INC. (VERA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Vera Therapeutics, INC.?

Forward-looking statements and predictions from Vera Therapeutics, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Vera Therapeutics, INC.. Recent 4 filing on Mar 25, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Vera Therapeutics, INC. on SEC EDGAR

Overview

Vera Therapeutics, INC. (VERA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Mar 25, 2026: This Form 4 filing, dated March 25, 2026, indicates that Jane Wright-Mitchell, a reporting person for Vera Therapeutics, Inc. (VTRA), has filed a statement of changes in beneficial ownership of securities. While the filing itself doesn't detail specific transactions, it signals that an insider's own

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 47 neutral. The dominant filing sentiment for Vera Therapeutics, INC. is neutral.

Filing Type Overview

Vera Therapeutics, INC. (VERA) has filed 1 3, 1 4, 23 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 4 SC 13G, 4 SC 13D/A, 1 DEFA14A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

Vera Therapeutics Insider Files Form 4 on Ownership Changes — 4 · Mar 25, 2026
This Form 4 filing, dated March 25, 2026, indicates that Jane Wright-Mitchell, a reporting person for Vera Therapeutics, Inc. (VTRA), has filed a statement of c
Vera Therapeutics: New Insider Jane Wright-Mitchell Files Initial Ownership — 3 · Mar 25, 2026
Jane Wright-Mitchell, a new insider at Vera Therapeutics, Inc., filed a Form 3 on March 25, 2026, indicating her initial beneficial ownership of securities. Thi
Vera Therapeutics Announces Board and Officer Changes — 8-K · Dec 18, 2025 Risk: low
Vera Therapeutics, Inc. announced on December 16, 2025, changes in its board and officer appointments. Specifically, the company reported the departure of certa
8-K Filing — 8-K · Dec 10, 2025
8-K Filing — 8-K · Nov 26, 2025
8-K Filing — 8-K · Nov 6, 2025
Vera Therapeutics' Losses Double Amid Soaring R&D Costs — 10-Q · Nov 5, 2025 Risk: high
Vera Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $208.5 million, a substantial rise fr
Vera Therapeutics Files 8-K on Agreements — 8-K · Aug 5, 2025 Risk: medium
On August 5, 2025, Vera Therapeutics, Inc. filed an 8-K report detailing the entry into and termination of material definitive agreements. The filing also inclu
Vera Therapeutics' Net Loss Widens Amid Rising R&D Costs — 10-Q · Aug 5, 2025 Risk: high
Vera Therapeutics, Inc. reported a net loss of $49.7 million for the three months ended June 30, 2025, an increase from a net loss of $40.1 million for the same
Vera Therapeutics Enters Material Definitive Agreement — 8-K · Jun 3, 2025 Risk: medium
Vera Therapeutics, Inc. entered into a Material Definitive Agreement on June 2, 2025, which also created a direct financial obligation for the registrant. The f
8-K Filing — 8-K · Jun 2, 2025
Vera Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · May 19, 2025 Risk: low
Vera Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting on matters submitted to a vote of security holders on May 14, 2025. The filing details the compa
Vera Therapeutics Files Q1 2025 10-Q — 10-Q · May 7, 2025 Risk: medium
Vera Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position, including cash and equivalents, and de
Vera Therapeutics Files 8-K on Financials — 8-K · May 6, 2025 Risk: low
Vera Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibit
Vera Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 3, 2025 Risk: low
Vera Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 3, 2025, for its annual meeting on May 14, 2025. The filing details information
10-K Filing — 10-K · Feb 28, 2025
Vera Therapeutics Files 8-K on Financials — 8-K · Feb 26, 2025 Risk: low
Vera Therapeutics, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing also includes financial st
Vera Therapeutics Files 8-K — 8-K · Jan 13, 2025 Risk: low
Vera Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G Filing — SC 13G · Nov 14, 2024
SC 13G Filing — SC 13G · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
Vera Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
Vera Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business
Longitude Capital Ups Vera Therapeutics Stake to 17.9% — SC 13D/A · Nov 4, 2024 Risk: medium
On November 4, 2024, Longitude Capital Partners IV, LLC, along with related entities and individuals including Patrick G. Enright and Juliet Tammenoms Bakker, f
Vera Therapeutics Files 8-K — 8-K · Oct 31, 2024 Risk: low
Vera Therapeutics, Inc. filed an 8-K on October 31, 2024, reporting an event that occurred on October 29, 2024. The filing is a current report pursuant to Secti
Vera Therapeutics Files 8-K Report — 8-K · Oct 28, 2024 Risk: low
On October 26, 2024, Vera Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 8000 Marina Boul
Vera Therapeutics Files 8-K — 8-K · Oct 2, 2024 Risk: low
On October 2, 2024, Vera Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits.
Vera Therapeutics Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
Vera Therapeutics, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhi
Vera Therapeutics Appoints New CMO, CSO, and Director — 8-K · Jul 2, 2024 Risk: medium
Vera Therapeutics, Inc. announced on June 26, 2024, the appointment of Dr. Laura Hansen as Chief Medical Officer and Dr. Jonathan Kay as Chief Scientific Office
Vera Therapeutics Appoints New CMO, Adds Director — 8-K · Jun 12, 2024 Risk: medium
Vera Therapeutics, Inc. announced on June 7, 2024, the appointment of Dr. Michael W. Gray as Chief Medical Officer and the election of Dr. Laura J. Shaw to its
Vera Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · May 17, 2024 Risk: low
Vera Therapeutics, Inc. filed an 8-K on May 17, 2024, reporting on matters submitted to a vote of security holders on May 15, 2024. The filing details the compa
Vera Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: medium
Vera Therapeutics, Inc. (VERA) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Vera Therapeutics, Inc. filed a 10-Q report for the period ending M
Vera Therapeutics Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
Vera Therapeutics, Inc. filed an 8-K on May 9, 2024, to report on its results of operations and financial condition, as well as to file financial statements and
Vera Therapeutics Files Proxy Statement Supplement — DEFA14A · May 3, 2024 Risk: low
Vera Therapeutics, Inc. filed a DEFA14A on May 3, 2024, to supplement its definitive proxy statement. This filing is considered definitive additional material a
Vera Therapeutics Announces 2024 Annual Meeting of Stockholders on May 15, 2024 — DEF 14A · Apr 3, 2024 Risk: low
Vera Therapeutics, Inc. (VERA) filed a Proxy Statement (DEF 14A) with the SEC on April 3, 2024. Vera Therapeutics, Inc. will hold its 2024 Annual Meeting of Sto
Vera Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 27, 2024 Risk: medium
Vera Therapeutics, Inc. (VERA) filed a Annual Report (10-K) with the SEC on March 27, 2024. Vera Therapeutics, Inc. filed its 2023 Form 10-K on March 27, 2024,
Sofinnova Amends Vera Therapeutics Stake — SC 13D/A · Mar 26, 2024 Risk: medium
Sofinnova Venture Partners X, L.P. and its affiliates, including Dr. James I. Healy and Dr. Maha Katabi, have amended their Schedule 13D filing regarding Vera T
Vera Therapeutics Files 8-K on Financials — 8-K · Mar 20, 2024 Risk: low
Vera Therapeutics, Inc. filed an 8-K on March 20, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhi
Sofinnova Amends Vera Therapeutics Stake — SC 13D/A · Feb 20, 2024 Risk: low
Sofinnova Venture Partners X, L.P. and its affiliates, including Sofinnova Management X, L.P. and Sofinnova Management X-A, L.L.C., filed an Amendment No. 3 to
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
Woodline Partners Discloses 5.1% Stake in Vera Therapeutics — SC 13G · Feb 12, 2024 Risk: low
Woodline Partners LP, a Delaware-based investment firm, reported owning 1,140,632 shares of Vera Therapeutics, Inc.'s Class A Common Stock as of December 31, 20
FMR LLC & Abigail Johnson Hold 6.243% Stake in Vera Therapeutics — SC 13G/A · Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Vera Therapeutics, Inc. (VTRA). As of Febru
Longitude Capital Amends Vera Therapeutics Stake — SC 13D/A · Feb 5, 2024
Longitude Capital Partners IV, LLC, along with its affiliates, filed an amended Schedule 13D on February 5, 2024, indicating a change in their beneficial owners
Vera Therapeutics Files 8-K for 'Other Event' on Jan 29 — 8-K · Jan 30, 2024
Vera Therapeutics, Inc. filed an 8-K on January 30, 2024, reporting an 'Other Event' that occurred on January 29, 2024. This filing indicates a routine update o
Vera Therapeutics Files 8-K on Financials & Other Events — 8-K · Jan 29, 2024
Vera Therapeutics, Inc. filed an 8-K on January 29, 2024, to report on its 'Results of Operations and Financial Condition' and 'Other Events.' This filing indic
BlackRock Discloses 5.0% Passive Stake in Vera Therapeutics — SC 13G · Jan 29, 2024
BlackRock, Inc. reported on January 29, 2024, that as of December 31, 2023, it beneficially owns 2,008,637 shares of Vera Therapeutics, Inc. Class A Common Stoc
Vera Therapeutics Files Routine 8-K; No Material Changes Reported — 8-K · Jan 25, 2024
Vera Therapeutics, Inc. filed an 8-K on January 25, 2024, to report a routine corporate event under Regulation FD Disclosure and Other Events. This filing prima

Risk Profile

Risk Assessment: Of VERA's 30 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Vera Therapeutics, INC.'s most recent 10-Q filing (Nov 5, 2025):

Revenue: $0
Net Income: -$208.5M
EPS: -$1.26
Debt-to-Equity: N/A
Cash Position: $497.4M
Operating Margin: N/A
Total Assets: N/A
Total Debt: $74.6M

Key Executives

Patrick G. Enright
Juliet Tammenoms Bakker
Laura Hansen
Jonathan Kay
Anya Schiach
Dr. Michael W. Gray
Dr. Laura J. Shaw
Dr. James I. Healy
Dr. Maha Katabi
Nathalie Auber
Abigail P. Johnson

Industry Context

Vera Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing treatments for immunological diseases. The industry is characterized by long development cycles, high failure rates in clinical trials, and significant regulatory scrutiny. Success hinges on innovation, robust clinical data, and substantial funding to navigate the path from discovery to commercialization.

Top Tags

corporate-governance (5) · financial-reporting (4) · sec-filing (4) · 8-K (4) · insider-ownership (3) · management-change (3) · filing (3) · 10-Q (3) · biotech (3) · SEC Filing (3)

Key Numbers

Net Loss: $208.5M — for the nine months ended September 30, 2025, up from $108.7M in 2024
Research and Development Expenses: $155.9M — for the nine months ended September 30, 2025, a 68% increase from $92.8M in 2024
General and Administrative Expenses: $65.3M — for the nine months ended September 30, 2025, more than double $25.4M in 2024
Accumulated Deficit: $669.8M — as of September 30, 2025, indicating significant historical losses
Cash, Cash Equivalents and Marketable Securities: $497.4M — as of September 30, 2025, down from $640.8M at December 31, 2024
Net Loss Per Share: $1.26 — for the three months ended September 30, 2025, compared to $0.85 in 2024
Shares Outstanding: 63,894,845 — as of September 30, 2025, up from 63,559,858 at December 31, 2024
Long-term Debt: $74.6M — as of September 30, 2025, up from $50.7M at December 31, 2024
Net Loss (Q2 2025): $49.7M — Increased from $40.1M in Q2 2024, indicating widening losses.
Net Loss (YTD Q2 2025): $97.8M — Increased from $77.8M in YTD Q2 2024, showing accelerated cash burn.
R&D Expenses (Q2 2025): $42.2M — Up from $33.4M in Q2 2024, driven by atacicept clinical trials.
Cash and Cash Equivalents (June 30, 2025): $300.0M — Decreased from $380.0M at December 31, 2024, reflecting cash burn.
Shares Issued: 1,000,000 — Class A common stock issued under 2024 Inducement Plan in February 2024.
Reporting Period End Date: 2025-03-31 — Indicates the end of the financial quarter being reported.
Q1 2025 R&D Expense Period: 2025-01-01 to 2025-03-31 — Covers the period for which Research and Development Expenses are reported.

Forward-Looking Statements

{"claim":"Vera Therapeutics' stock price may see a short-term positive reaction due to increased institutional interest.","entity":"Vera Therapeutics, Inc.","targetDate":"Q1 2024","confidence":"medium"}
{"claim":"Other institutional investors might review Vera Therapeutics more closely following Woodline Partners' significant stake.","entity":"Vera Therapeutics, Inc.","targetDate":"Q2 2024","confidence":"medium"}
{"claim":"FMR LLC will maintain a significant, passive stake in Vera Therapeutics for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}

Related Companies

VTRA · VTRS

Frequently Asked Questions

What are the latest SEC filings for Vera Therapeutics, INC. (VERA)?

Vera Therapeutics, INC. has 50 recent SEC filings from Jan 2024 to Mar 2026, including 23 8-K, 7 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of VERA filings?

Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 47 neutral. The dominant sentiment is neutral.

Where can I find Vera Therapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Vera Therapeutics, INC. (VERA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Vera Therapeutics, INC.?

Key financial highlights from Vera Therapeutics, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for VERA?

The investment thesis for VERA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Vera Therapeutics, INC.?

Key executives identified across Vera Therapeutics, INC.'s filings include Patrick G. Enright, Juliet Tammenoms Bakker, Laura Hansen, Jonathan Kay, Anya Schiach and 6 others.

What are the main risk factors for Vera Therapeutics, INC. stock?

Of VERA's 30 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 18 low-risk.

What are recent predictions and forward guidance from Vera Therapeutics, INC.?

Recent forward-looking statements from Vera Therapeutics, INC. include guidance on {"claim":"Vera Therapeutics' stock price may see a short-term positive reaction due to increased institutional interest. and 2 other predictions.